BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Alembic Pharma Eyes US Growth, Margins in Animal Health Business

Synopsis:

Alembic Pharmaceuticals posted a 17% YoY revenue growth to Rs.1,770 crore in Q4FY25, while net profit fell 9% to Rs.162 crore. EBITDA margins slipped to 15.4%.


Alembic Pharmaceuticals is maintaining a steady growth trajectory in the US market despite broader industry uncertainties. Backed by stable product volumes and a strong pipeline of upcoming launches, the company expects its US business to remain resilient in the near term. At the same time, its animal health division continues to show operational improvements, with efforts underway to push segmental margins closer to the 20% mark.

Also read: Suven Pharma Renamed Cohance Lifesciences After Merger Completion

ALEMBIC PHARMACEUTICALS LTD.

Trade

902.155.30 (0.59 %)

Updated - 08 May 2025
906.70day high
DAY HIGH
885.60day low
DAY LOW
44029
VOLUME (BSE)

Key Takeaways

  1. Q4FY25 revenue rose 17% YoY to Rs.1,770 crore.

  2. EBITDA grew 5% YoY to Rs.272 crore, but margins fell to 15.4%.

  3. Net profit declined 9% YoY to Rs.162 crore.

  4. Alembic targets 20% margins in animal healthcare business.

  5. Alembic Pharmaceuticals share price has declined nearly 14% over the past year.

Also read: JBM Auto Aims Rs.6,500 Crore Revenue by FY26, Rides EV Growth Wave

Despite margin pressure, the company has retained its focus on expanding its US portfolio and scaling up manufacturing capabilities to capitalise on upcoming opportunities. The recent US executive order aimed at domestic pharmaceutical manufacturing has not impacted Alembic’s business yet, with steady performance observed in key therapeutic categories.

The animal health vertical, meanwhile, is gaining traction. This segment, which caters to veterinary drugs and feed supplements, is being optimised through operational efficiencies and cost control initiatives. Alembic expects this area to play a vital role in long-term profitability.

Financial Snapshot – Q4 FY25

Metric

Q4 FY25

Q4 FY24

Change (%)

Revenue (Rs. crore)

1,770

1,517

+17%

EBITDA (Rs. crore)

272

260

+5%

EBITDA Margin (%)

15.4

17.1

-170 bps

Net Profit (Rs. crore)

162

178

-9%

Market Capitalisation (Rs. crore)

17,427

-

-

While Alembic Pharmaceuticals share price continues to face pressure in the equity markets, the company’s operational performance and strategic focus on high-margin businesses could offer upside potential in the medium term. The near-term outlook remains cautious but stable.

Also read: Newgen Software Targets 20% Growth, US Market to Lead Expansion

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text